BCL2 and malignant colon neoplasm: The percentage of Bcl-2 and p53 immunopositivity (70 and 50%, respectively) is in good accordance with the results of a non-metastatic colon cancer study using both the same antibodies and the same scoring system as we did, thereby detecting cytoplasmic Bcl-2 and nuclear p53 immunopositivity in 66 and 48% of 110 cases, respectively (Sinicrope et al, 1995).